Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Key value for chemical safety assessment

Effects on fertility

Description of key information

- study conducted according to OECD guideline EPA OPP 83-3 (Prenatal Developmental Toxicity Study), GLP, Sprague-Dawley rats were exposed to 100, 300, and 1000 mg/kg bw/day administered undiluted once a day for 10 days from gd6 through gd15 and observed for 22days (gd21), no teratogenic properties, NOEL = 1000 mg a.i./kg bw/d, NOEL (maternal toxicity) = 1000 mg a.i./kg bw/d, read-across, partially unsaturated IQCAs, DMS quaternised (75%)

- study conducted similar to EPA OPPTS 870.3700 (Prenatal Developmental Toxicity Study), similar to GLP, Sprague-Dawley rats were exposed to 200, 350, 610, 1075, and 1875 mg/kg bw/day (referring to 100 % active substance) for 10 days from gd6 through gd15 and observed for 22days (gd21), no maternal toxicity, embryotoxicity, or developmental toxicity up to the highest dose, read-across, partially unsaturated IQCAs, DMS quaternised (75%)

Link to relevant study records
Reference
Endpoint:
screening for reproductive / developmental toxicity
Data waiving:
study scientifically not necessary / other information available
Justification for data waiving:
other:
Reproductive effects observed:
not specified
Effect on fertility: via oral route
Endpoint conclusion:
no adverse effect observed
Dose descriptor:
NOAEL
1 000 mg/kg bw/day
Study duration:
subchronic
Species:
rat
Quality of whole database:
High quality, guideline study
Effect on fertility: via inhalation route
Endpoint conclusion:
no study available
Effect on fertility: via dermal route
Endpoint conclusion:
no study available
Additional information

No experimental data on Toxicity to reproduction are available for the target substance hydrogenated tallow/nortallow based IQACs. However, a study is available for the source substance partially unsaturated IQAC, DMS quaternised (tallow fatty acids). A detailed justification for read-across is attached to IUCLID section 13.

In the 91-days repeated dose study, Sprague-Dawley rats were treated with partially unsaturated IQAC, DMS quaternised (tallow fatty acids) by application in the feed at doses of up to 1000 mg/kg bw/d of active ingredient. No treatment related effects were observed on the reproductive organs of either gender. Fertility studies are not available and not necessary at the production volume of this substance. Also, the dossier contains either the results of, or a testing proposal for, a pre-natal developmental toxicity study.


Short description of key information:
Concerning fertility there are no animal studies specifically investigating this endpoint. However, no effects on organ weights of ovary and testes and histopathology of gonads from a 91-day repeated dose study were reported. There is no information available in humans.
Assessment of effects on fertility via inhalation is not applicable due to the very low vapour pressure of the test substance and the absence of aerosols.

Effects on developmental toxicity

Description of key information

- study conducted according to OECD guideline EPA OPP 83-3 (Prenatal Developmental Toxicity Study), GLP, Sprague-Dawley rats were exposed to 100, 300, and 1000 mg/kg bw/day administered undiluted once a day for 10 days from gd6 through gd15 and observed for 22days (gd21), no teratogenic properties, NOEL = 1000 mg a.i./kg bw/d, NOEL (maternal toxicity) = 1000 mg a.i./kg bw/d, read-across, partially unsaturated IQCAs, DMS quaternised (75%)

- study conducted similar to EPA OPPTS 870.3700 (Prenatal Developmental Toxicity Study), similar to GLP, Sprague-Dawley rats were exposed to200, 350, 610, 1075, and 1875 mg/kg bw/day (referring to 100 % active substance) for 10 daysfrom gd6 through gd15 and observed for 22days (gd21), no maternal toxicity, embryotoxicity, or developmental toxicity up to the highest dose, read-across, partially unsaturated IQCAs, DMS quaternised (75%)

Link to relevant study records

Referenceopen allclose all

Endpoint:
developmental toxicity
Type of information:
experimental study
Adequacy of study:
key study
Study period:
1991-05-13 to 1992-04-23
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
other: guideline Study
Qualifier:
according to guideline
Guideline:
EPA OPP 83-3 (Prenatal Developmental Toxicity Study)
Deviations:
no
GLP compliance:
yes
Limit test:
no
Species:
rat
Strain:
Sprague-Dawley
Details on test animals or test system and environmental conditions:
Test animals
- Age: Males approx. 63 days; Females: approx. 56 days
- Weight: Males 265 – 320 g upon arrival; Females 172 – 200 g upon arrival
- Fasting period before study: no data given
- Housing: Before mating males were housed singly, females were housed two to a cage.
- During mating 1 male and 1 female were housed individually.
- After mating copulation plug positive females and therefore considered successfully mated
- were housed singly for the duration of the study in stainless steel wire mesh cages.
- Diet: Access ad libitum; Ground Certified Rodent Chow ® (#5002, Ralston Purina Co., St. Louis, MO).
- Water: ad libitum, municipal tap water
- Acclimation period: approx. 2 wks
Environmental Conditions
- Temperature (°C): 19 – 25
- Humidity (%): relative 40 – 70
- Photoperiod: 12 hrs dark/12 hrs light; light period 5 – 17 hrs

In-Life dates: From May 27-30, 1991 to June 14 (gd 15); May 28 – 30, 1991 was gd0.
- Treatment began on gd6 (June 3-5, 1991). Dams were sacrificed on gd21 (June 18 – 20, 1991)
Route of administration:
oral: gavage
Vehicle:
unchanged (no vehicle)
Details on exposure:
Preparation of dosing solutions:
Control: Milli-Q ® water, volume according to highest test substance volume selected (1,42
ml / kg bw/day)
Dose levels: The dose levels referring to the active ingredient were 100, 300, and 1000
mg/kg bw/day administered undiluted once a day, based on the dam's body weight on
gestational day 6, the percent active ingredient (76,6%) and the specific gravity of the test
substance (0,92 g/cm3). Dosage volumes were not changed to account for increases in
gestational body weight after gd6. Accordingly the applied test substance volumes were
0,142, 0,426, and 1,42 mg/kg bw/day
Analytical verification of doses or concentrations:
no
Details on analytical verification of doses or concentrations:
not applicable
Details on mating procedure:
Proof of pregnancy: Females were checked once daily for vaginal copulation plugs in the
morning and the paperboard beneath the cages was checked twice daily for dropped
copulation plugs. The observation of a vaginal or dropped copulation plug was considered
evidence of successful mating. Each male was paired only once in this study.
Duration of treatment / exposure:
10 days, from gd6 through gd15
Frequency of treatment:
once daily
Duration of test:
22 days (till gd21)
No. of animals per sex per dose:
25; Evaluated pregnant rats: group 1-4: 21/23/22/25 (females with viable fetuses)
Animals evaluated for maternal toxicity: group 1-4: 22/23/24/25
Control animals:
yes, concurrent vehicle
Details on study design:
Dose selection rationale: Based on a former dose range finding study
Rationale for animal assignment (if not random): The rat is a commonly used rodent species for embryotoxic studies.
Group size per dose level: 22/23/23/25 pregnant animals per dose group
Maternal examinations:
Cage side observations: yes
Time schedule: daily

Detailed clinical observations: Yes
Time schedule: daily

Clinical signs: Yes
daily observations for behavior, external appearance and general condition

Viability: Yes
daily checks twice daily for morbidity and mortality

Body weight: yes
Time schedule for examinations: Maternal body weights were taken on gd0, gd6 (prior to the onset of dosing), gd9, 12, 15, 18, and 21

Food consumption: yes
Food consumption was measured at three-day intervals throughout the study (gd0 through 21).

Water consumption: no

Post-mortem examinations: Yes
Organs examined: Macroscopic examination of uteri, ovaries, cervix, vagina, peritoneal and thoracic cavities.
Maternal liver and Gravid Uteri weights, Number of Corpora lutea, Number and status of Implantation sites.


Ovaries and uterine content:
The ovaries and uterine content was examined after termination: Yes
Examinations included:
Gravid Uterus weight: yes
Number of corpora lutea: yes
Number of implantations: yes
Number of early resorptions: yes
Number of late resorptions: yes
Fetal examinations:
Fetal examinations
External examinations: yes: all litter
Soft tissue examinations: yes; approx. 50%
Skeletal examinations: yes, 50%
Head examinations: yes
other: Number of fetuses (live and dead), sex and viability of fetuses, variations and malformations, including cleft palate
Statistics:
Levene's test for equality of variances, analysis of variance (ANOVA) and t-tests. The t-tests
were used when the F value from the ANOVA was significant. When Levene's test indicated
equal variances, and the ANOVA was significant, a pooled t-test was used for pair wise
comparisons. When Levene's test indicated heterogeneous variances, all groups were
compared by an ANOVA for unequal variances followed, when necessary, by a separate
variance t-test for pair wise comparisons.
Nonparametric data were statistically evaluated using the Kruskal-Wallis test, followed by the
Mann-Whiney U test when appropriate. Incidence data were compared using the Fisher's
Exact Test. With the exception of analyses for fetal malformation and variation data, all
statistical evaluations were performed using BMDP Statistical Software (Dixon, 1990). For all
statistical tests, the probability value of <0,05 (two-tailed) was used as the critical level of
significance.
Clinical signs:
effects observed, non-treatment-related
Description (incidence and severity):
300 mg/kg bw/day dose group:
2 dams exhibited audible respiration during or subsequent to the treatment period.
One dam exhibited swelling in the face, urogenital area wetness, gasping and perinasal and perioral encrustation. This animal was sacrificed due to her moribund condition on gd10. None of these signs were considered to be test substance related due to their absence in the dose range finding study up to doses of 1875 mg/kg bw/day and the lack of any dose relation in the current study.

1000 mg/kg bw/day dose group:
3 dams exhibited audible respiration during or subsequent to the treatment period.
No treatment-related differences in gestational parameters including total number of implantations, number of viable and nonviable implants in any dose group.
Dermal irritation (if dermal study):
not examined
Mortality:
mortality observed, non-treatment-related
Description (incidence):
Mortality:
300 mg/kg bw/day dose group: One female became moribund and was sacrificed on gd10.
Body weight and weight changes:
no effects observed
Description (incidence and severity):
No treatment-related effects on gestational body weights and body weight gain, corrected body weight, corrected body weight gain, absolute and relative liver weight, and gravid uterine weight .
Food consumption and compound intake (if feeding study):
effects observed, non-treatment-related
Description (incidence and severity):
Increased food consumption in the 100 mg/kg bw/day dose group was not considered to be related to treatment due to the lack of a dose-relationship.
Food efficiency:
not examined
Water consumption and compound intake (if drinking water study):
not examined
Ophthalmological findings:
not examined
Haematological findings:
no effects observed
Clinical biochemistry findings:
no effects observed
Urinalysis findings:
not examined
Behaviour (functional findings):
not examined
Immunological findings:
not examined
Organ weight findings including organ / body weight ratios:
no effects observed
Gross pathological findings:
effects observed, non-treatment-related
Description (incidence and severity):
One female in the 300 mg/kg bw/day dose group which was sacrificed due to her moribund condition, had gas-filled intestines, mucoid fluid or material in the nose turbinates, abnormal material in the trachea and discolored and consolidated lungs. One further animal in this dose group had no implants in one uterine horn. Two females in the 1000 mg/kg bw/day dose group contained blood in the uterus (detected with Hemastix reagent strips) One further female had discolored lungs (dark red) in all lobes.

Neuropathological findings:
not examined
Histopathological findings: non-neoplastic:
no effects observed
Histopathological findings: neoplastic:
not examined
Other effects:
no effects observed
Number of abortions:
no effects observed
Pre- and post-implantation loss:
no effects observed
Total litter losses by resorption:
effects observed, non-treatment-related
Description (incidence and severity):
Resorptions: 10 (0.5 per dam), 7 (0.4 per dam), 12 (0.5 per dam), 53 (2.7 per dam)**
Early or late resorptions:
no effects observed
Description (incidence and severity):
Early resorptions:13 (0.6 per dam), 21 (0.9 per dam), 17 (0.7 per dam), 14 (0.6 per dam)
Late resorptions:0 (0 per dam), 1 (0 per dam), 2 (0.1 per dam), 0 (0 per dam)
Dead fetuses:
no effects observed
Description (incidence and severity):
Live (Viable) fetuses:327 (14.9 per dam), 356 (15.5 per dam), 343 (14.3 per dam), 367 (14.7 per dam)
Changes in pregnancy duration:
no effects observed
Changes in number of pregnant:
no effects observed
Description (incidence and severity):
Implantation sites (Total implants): 340 (15.5 per dam), 379 (16.5 per dam)*, 363 (15.7 per dam)**, 382 (15.3 per dam)
Other effects:
no effects observed
Description (incidence and severity):
Corpora lutea:338 (16.1 per dam), 380 (16.5 per dam), 364 (15.7 per dam), 387 (15.5 per dam)
Details on maternal toxic effects:
Maternal toxic effects:no effects

Details on maternal toxic effects:
No substance related maternal toxicity detected up to the highest dose tested.
Key result
Dose descriptor:
NOEL
Effect level:
>= 1 000 mg/kg bw/day
Based on:
test mat.
Basis for effect level:
other: maternal toxicity
Key result
Abnormalities:
no effects observed
Fetal body weight changes:
no effects observed
Description (incidence and severity):
Fetal body weights per litter were not affected by treatment.
Reduction in number of live offspring:
no effects observed
Changes in sex ratio:
no effects observed
Changes in litter size and weights:
effects observed, non-treatment-related
Description (incidence and severity):
No treatment related effects on fetal body weights (all fetuses, male or female) observed in any group. The statistically significant* differences in mean male and female body weights in litters at 100 mg/kg bw/day were not considered to be treatment-related due to the lack of a dose-response relationship.
Changes in postnatal survival:
not examined
External malformations:
no effects observed
Description (incidence and severity):
none significantly different from Control
Skeletal malformations:
effects observed, non-treatment-related
Description (incidence and severity):
Findings: Anterior arch of atlas poorly ossified; Statistical significance of affected litters in 1000 mg/kg bw/day dose group; % affected litters (71.4, 87.0, 86.4 96.0*)
Findings: Majority of forelimbs unossified; Statistical significance of affected litters in 300 mg/kg bw/day dose group; % affected litters (38.1, 26.1, 4.5**, 24.0)
Visceral malformations:
no effects observed
Other effects:
no effects observed
Description (incidence and severity):
Other External variations (fetal incidence): none significantly different from control
Details on embryotoxic / teratogenic effects:
Embryotoxic / teratogenic effects:no effects

Details on embryotoxic / teratogenic effects:
No embryotoxicity or teratogenicity detected up to the highest dose tested
Key result
Dose descriptor:
NOEL
Effect level:
>= 1 000 mg/kg bw/day
Based on:
test mat.
Sex:
male/female
Basis for effect level:
other: embryotoxicity
Key result
Abnormalities:
not specified
Developmental effects observed:
not specified

TOXIC RESPONSE/EFFECTS BY DOSE LEVEL:

Mortality:

300 mg/kg bw/day dose group:

One female became moribund and was sacrificed on gd10.

Clinical signs:

300 mg/kg bw/day dose group:

2 dams exhibited audible respiration during or subsequent to the treatment period.

One dam exhibited swelling in the face, urogenital area wetness, gasping and perinasal and perioral

 encrustation. This animal was sacrificed due to her moribund condition on gd10. None of these signs

were considered to be test substance related due to their absence in the dose range finding study up

to doses of 1875 mg/kg bw/day and the lack of any dose relation in the current study.

1000 mg/kg bw/day dose group:

3 dams exhibited audible respiration during or subsequent to the treatment period.

No treatment-related differences in gestational parameters including total number of implantations,

 number of viable and nonviable implants in any dose group.

Body weight:

No treatment-related effects on gestational body weights and body weight gain, corrected body

weight, corrected body weight gain, absolute and relative liver weight, and gravid uterine weight .

Fetal body weights per litter were not affected by treatment.

Increased food consumption in the 100 mg/kg bw/day dose group was not considered to be related to

treatment due to the lack of a dose-relationship.

NECROPSY FINDINGS IN DAMS AT TERMINATION:

One female in the 300 mg/kg bw/day dose group which was sacrificed due to her moribund

condition, had gas-filled intestines, mucoid fluid or material in the nose turbinates, abnormal

material in the trachea and discolored and consolidated lungs. One further animal in this

dose group had no implants in one uterine horn.

Two females in the 1000 mg/kg bw/day dose group contained blood in the uterus (detected

with Hemastix reagent strips) One further female had discolored lungs (dark red) in all lobes.

REPRODUCTION DATA OF DAMS (0, 100, 300, 1000 mg/kg bw):

-         Corpora lutea:338 (16.1 per dam), 380 (16.5 per dam), 364 (15.7 per dam), 387 (15.5 per dam)

-         Implantation sites (Total implants): 340 (15.5 per dam), 379 (16.5 per dam)*, 363 (15.7 per dam)**, 382 (15.3 per dam)

-         Resorptions: 10 (0.5 per dam), 7 (0.4 per dam), 12 (0.5 per dam), 53 (2.7 per dam)**

-         Early resorptions:13 (0.6 per dam), 21 (0.9 per dam), 17 (0.7 per dam), 14 (0.6 per dam)

-         Late resorptions:0 (0 per dam), 1 (0 per dam), 2 (0.1 per dam), 0 (0 per dam)

-         Live (Viable) fetuses:327 (14.9 per dam), 356 (15.5 per dam), 343 (14.3 per dam), 367 (14.7 per dam)

-         Malformations (external, skeletal, soft tissue) (fetal incidence): none significantly different from Control

-         Skeletal variations (fetal incidence):

-         Findings: Anterior arch of atlas poorly ossified; Statistical significance of affected litters in 1000 mg/kg bw/day dose group;

% affected litters (71.4, 87.0, 86.4 96.0*)

-         - Skeletal variations (fetal incidence):

-         Findings: Majority of forelimbs unossified; Statistical significance of affected litters in 300 mg/kg bw/day dose group;

% affected litters (38.1, 26.1, 4.5**, 24.0)

-         - Soft Tissue variations (fetal incidence):

-         Findings: Excessive bleeding at umbilicus; Statistical significance of affected litters in 100 mg/kg bw/day dose group;

% affected litters (23.8, 0*, 27.3, 40.0)

-         Other External variations (fetal incidence): none significantly different from control


   Weight of fetuses: No treatment related effects on fetal body weights (all fetuses, male or female)

observed in any group. The statistically significant* differences in mean male and female body

weights in litters at 100 mg/kg bw/day were not considered to be treatment-related due to the lack

of a dose-response relationship.

* Significantly different from control, p= 0.05 using two-tailed Fisher's exact test

** Significantly different from control, p= 0.01 using two-tailed Fisher's exact test



Conclusions:
In conclusion the test item partially unsaturated IQAC, DMS quaternised possessed no teratogenic properties, not even at the highest dose tested . Embryotoxicity was not observed.
Therefore the NOEL was 1000 mg active ingredient/kg bw/day. The NOEL for maternal toxicity was 1000 mg active ingredient/kg bw/day.
Executive summary:

In a developmental toxicity study according to OPP 83-3 the partially unsaturated IQAC, DMS quaternised (75%) was administered to 25 female Sprague CD rats/dose by gavage at dose levels of 0, 100, 300, and 1000 mg/kg bw/day referring to 100 % active substance from day 6 through 15 of gestation. The maternal NOEL is 1000 mg active substance/kg bw/day, based on the lack of effects indicating maternal toxicity.

Likewise, the embryotoxic NOEL is 1000 mg active substance/kg bw/day, based on the lack of embryotoxic effects up to the highest dose level.

The teratogenic NOEL is 1000 mg active substance/kg bw/day.

The partially unsaturated IQAC, DMS quaternised showed no teratogenic properties (no incidence of malformations). The observed variations were isolated without dose relation or lower than in the control group and were therefore not regarded as treatment related.

The developmental toxicity study in the rat is classified acceptable and satisfies the guideline requirement for a developmental toxicity study (OPPTS 870.3700) in rats.

These findings are further backed by the lack of adverse effects in a dose range finding study which was conducted up to a dose level of 1875 mg/kg bw/day.

Endpoint:
developmental toxicity
Type of information:
experimental study
Adequacy of study:
supporting study
Study period:
1991-03-26 to 1993-02-17
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: study comparable to Guideline
Qualifier:
no guideline required
Principles of method if other than guideline:
similar to EPA OPPTS 870.3700 (Prenatal Developmental Toxicity Study)
GLP compliance:
yes
Limit test:
no
Species:
rat
Strain:
Sprague-Dawley
Details on test animals or test system and environmental conditions:
Details on test animals and environmental conditions
Test animals
- Source: Charles River Breeding Laboratories, Inc. (Partage, MT)
- Age: Males approx. 64 days; Females: approx. 57 days
- Weight: Males 260 – 325 g upon arrival; Females 172 – 210 g upon arrival
- Fasting period before study: no data given
- During mating 1 male and 1 female were housed individually.
- After mating copulation plug positive females and therefore
- considered successfully mated were housed singly for the duration of the study in stainless steel wire mesh cages.
- Each male was paired only once in this study.
- Diet: Access ad libitum; Ground Certified Rodent Chow ® (#5002, Ralston Purina Co., St. Louis, MO).
- Water: ad libitum, municipal tap water
- Acclimation period: approx. 2 wks
Environmental Conditions
- Temperature (°C): 19 – 25
- Humidity (%): relative 40 – 70
- Photoperiod: 12 hrs dark/12 hrs light; light period 5 – 17 hrs
Route of administration:
oral: gavage
Vehicle:
unchanged (no vehicle)
Analytical verification of doses or concentrations:
no
Details on mating procedure:
Details on mating procedure
Proof of pregnancy: Females were checked once daily for vaginal copulation plugs in the morning and the paperboard beneath
the cages was checked twice daily for dropped copulation plugs. The observation of a vaginal or dropped copulation plug was
considered evidence of successful mating. Each male was paired only once in this study.
Duration of treatment / exposure:
10 days, from gd6 through gd15
Frequency of treatment:
once daily
Duration of test:
22 days (till gd21)
No. of animals per sex per dose:
5
Control animals:
yes, concurrent no treatment
Details on study design:
The objective of this study was to obtain information from which to select dosage levels for a subsequent developmental toxicity study of the test substance.
Maternal examinations:
Maternal examinations
Cage side observations: yes
Time schedule: daily
Details on maternal toxic effects:
Maternal toxic effects:no effects
Dose descriptor:
NOAEL
Effect level:
>= 1 875 mg/kg bw/day (actual dose received)
Based on:
act. ingr.
Basis for effect level:
other: maternal toxicity
Dose descriptor:
NOAEL
Effect level:
>= 1 875 mg/kg bw/day (actual dose received)
Based on:
act. ingr.
Basis for effect level:
other: developmental toxicity
Details on embryotoxic / teratogenic effects:
Embryotoxic / teratogenic effects:no effects
Abnormalities:
not specified
Developmental effects observed:
not specified

In a developmental toxicity Range-Finding study the partially unsaturated IQAC; DMS quaternised (75%) was administered to 5 pregnant female CD rats/dose by gavage at dose levels of 200, 350, 610, 1075, and 1875 mg/kg bw/day (referring to 100 % active substance) from day 6 through 15 of gestation. An additional 5 females, assigned to the control group, received Milli ®-Q water at a dose volume equivalent to that used in the high dose group.

Clinical observations were made daily (twice daily during dosing), and maternal body weights were measured at three-day intervals throughout gestation, gd 0-21. At scheduled sacrifice on gd 21, the dams were evaluated for liver and gravid uterine weights, number of corpora lutea and number and status of implantation sites, including early and late resorptions, dead and live fetuses. All live and dead fetuses were dissected from the uterus, weighed and examined for sex determinations and external malformations, including cleft palates and variations.

There were no treatment-related effects on clinical signs of toxicity, food consumption, gestational body weight and body weight gain, corrected body weight, corrected body weight gain, and gravid uterine weight.

No treatment related differences in gestational parameters including total number of implantations, number of viable and non-viable implants, were observed in any dose group.

No females died prior to scheduled sacrifice. No females aborted, delivered early or were removed from the study.

At scheduled sacrifice, one female in the 1075 mg/kg bw/day group found to be non-pregnant and another animal from this group contained only non-viable fetuses. All other animals were pregnant and bore at least one viable fetus.

Fetal body weights per litter were not affected by treatment. No treatment-related external malformations or variations were observed in this study.

Conclusions:
Administration of the test item partially unsaturated IQAC, DMS quaternised (75%) by gavage to pregnant CD ® Sprague Dawley rats during organogenesis resulted in no maternal toxicity, embryotoxicity, or developmental toxicity at dosages up to 1875 mg a.i./kg bw/day. On the basis of this study, target doses selected for the definitive developmental toxicity study were 0, 100, 300, and 1000 mg a.i./kg bw/day.
Effect on developmental toxicity: via oral route
Dose descriptor:
NOAEL
1 000 mg/kg bw/day
Study duration:
subchronic
Species:
rat
Quality of whole database:
high quality, guideline study
Effect on developmental toxicity: via inhalation route
Endpoint conclusion:
no study available
Effect on developmental toxicity: via dermal route
Endpoint conclusion:
no study available
Additional information

No experimental data on Toxicity to reproduction are available for the target substance hydrogenated tallow/nortallow based IQACs. However, a study is available for the source substancepartially unsaturated IQAC, DMS quaternised (tallow fatty acids). A detailed justification for read-across is attached to IUCLID section 13.

The test item partially unsaturated IQAC, DMS quaternised (tallow fatty acids, 75 %) possessed no teratogenic properties, not even at the highest dose tested. Embryotoxicity was not observed. Therefore the NOEL was 1000 mg partially unsaturated IQAC, DMS quaternised (tallow fatty acids) (75 %) active ingredient/kg bw/day. The NOEL for maternal toxicity was 1000 mg partially unsaturated IQAC, DMS quaternised (tallow fatty acids) (75 %) active ingredient/kg bw/day based on the lack of effects indicative of maternal toxicity.

Justification for classification or non-classification

There is no evidence for an intrinsic toxicity to reproduction of partially unsaturated IQAC, DMS quaternised from the results of a reliable oral developmental toxicity / teratogenicity study on rats at doses including the guideline limit dose of 1000 mg a. i./kg bw/day and reliable oral sub-chronic repeated dose toxicity data, where no treatment related effects were observed on the reproductive organs of either gender at 1000 mg/kg bw/day.

Therefore also no classification is required for toxicity to reproduction according to CLP, EU GHS (Regulation (EC) No 1272/2008) and directive 67/548/EEC for the target substance hydrogenated tallow/nortallow based IQACs.

Additional information